Back to search resultsSummaryRMgm-154
|
||||||||
*RMgm-154| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) | Gene disruption |
| Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 16796674 |
| MR4 number | |
| top of page | |
| Parent parasite used to introduce the genetic modification | |
| Rodent Malaria Parasite | P. berghei |
| Parent strain/line | P. berghei ANKA |
| Name parent line/clone | P. berghei ANKA 2.34 |
| Other information parent line | P. berghei ANKA 2.34 is a cloned, gametocyte producer line of the ANKA strain (PubMed: PMID: 15137943). |
| top of page | |
| The mutant parasite was generated by | |
| Name PI/Researcher | I. Siden-Kiamos; O. Billker |
| Name Group/Department | Division of Cell and Molecular Biology |
| Name Institute | Imperial College London |
| City | London |
| Country | United Kingdom |
| top of page | |
| Name of the mutant parasite | |
| RMgm number | RMgm-154 |
| Principal name | cdpk3- |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | Yes |
| top of page | |
| Phenotype | |
| Asexual blood stage | Not different from wild type |
| Gametocyte/Gamete | Not different from wild type |
| Fertilization and ookinete | Normal numbers of ookinetes are produced. These ookinetes have a (light microscope) morphology that is comparable to wild type ookinetes. Ookinetes show a strong reduction (98%) in the formation of oocysts in A. stephensi mosquitoes. Ookinetes fail to associate with the midgut epithelium. Ookinetes showed a strongly reduced ability to glide productively. |
| Oocyst | Ookinetes show a strong reduction (98%) in the formation of oocysts in A. stephensi mosquitoes. Injection of in vitro cultured, mature ookinetes into the hemocoel and thereby by-passing the midgut wall resulted in normal development of oocysts and infectious sporozoites. |
| Sporozoite | Not different from wild type |
| Liver stage | Not different from wild type |
| Additional remarks phenotype | Mutant/mutation Disruption of the P. falciparum ortholog has been attempted (Solyakov et al., 2011, Nat Commun, 2:565). |
Disrupted: Mutant parasite with a disrupted gene| top of page | |||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PBANKA_0408200 | ||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_0310100 | ||||||||||||||||||||||||
| Gene product | calcium-dependent protein kinase 3 | ||||||||||||||||||||||||
| Gene product: Alternative name | CDPK3 | ||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||
| Inducable system used | No | ||||||||||||||||||||||||
| Additional remarks inducable system | |||||||||||||||||||||||||
| Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||
| Restriction sites to linearize plasmid | KpnI/BamHI | ||||||||||||||||||||||||
| Partial or complete disruption of the gene | Partial | ||||||||||||||||||||||||
| Additional remarks partial/complete disruption |
5' targetting region: a 608 bp fragment comprising 5′ upstream sequence followed by the first 543 bp of exon1 of cdpk3 3' targetting region: A 686 bp fragment comprising the last two exons and 3′ flanking region of pbcdpk3 No additional information on primer sequences is available. | ||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
| Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||
| Additional remarks genetic modification | No additional information on primer sequences used for the replacement construct is provided in the paper! | ||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||
|
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||